Abbott Laboratories is a diversified healthcare company incorporated in 1900 that discovers, develops, manufactures, and sells products across four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The pharmaceutical segment offers branded generics for gastroenterology, women’s health, cardiovascular, pain, respiratory, and biologic therapies, marketed primarily in emerging markets outside the United States. The diagnostic segment provides laboratory systems, molecular diagnostics, point-of-care testing, and rapid diagnostics for infectious diseases, oncology, and transfusion medicine. The nutritional segment supplies infant formula, adult nutritional products, and enteral feeding solutions for consumers and healthcare institutions. The medical devices segment includes cardiovascular rhythm management, electrophysiology, heart failure, vascular, and structural heart devices, as well as diabetes care and continuous glucose monitoring products and neuromodulation devices for chronic pain and movement disorders. Abbott sells its products globally to hospitals, laboratories, clinics, wholesalers, retailers, government agencies, and consumers.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage abbott.com
Sector Healthcare IR page abbott.com/en-us/homepage
Tags
diagnostic testing, continuous glucose monitoring, cardiovascular devices, neuromodulation, infant formula, branded generics, point-of-care testing, laboratory automation, molecular diagnostics, chronic pain management, Creon, Duspatal, Dicetel, Heptral, Transmetil, Samyr, Duphalac, Duphaston, Femoston, Lipanthyl, TriCor, Omacor, Physiotens, Synthroid, Serc, Brufen, Sevedol, Klacid, Claribid, Klaricid, Influvac, Alinity, ARCHITECT, Cell-Dyn, m2000, Vysis, i-STAT, BinaxNOW, Panbio, m-PIMA, ID NOW, Afinion, Cholestech LDX, Track, AlinIQ, Indexor, RALS, Similac, Go & Grow, EleCare, Gain, Grow, Ensure, Glucerna, ProSure, PediaSure, Juven, Abound, Pedialyte, Jevity, Osmolite, Oxepa, Freego, Nepro, Vital, Lingo Glucose System
Press page abbott.com/en-us/corpnewsroom/press-releases

Metrics

Valuation  
Market cap $ 200.905B
Market cap (USD) $ 200.905B
P/E 43.28
PEG —
P/BV 3.94
P/S 4.17
P/OCF 22.69
P/FCF 29.73
Dividend yield 2.2%
Turnover / mcap —
Returns  
ROE 13.1%
ROI 10.0%
ROIC 9.5%
Profit margin 14.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -2.0%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 61.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 30
Quality score 10.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 44.328B 41.95B 40.109B 43.653B 43.075B 34.608B 31.904B 30.578B 27.39B 20.853B 20.405B 20.247B 21.848B 39.874B 38.851B 35.167B 30.765B 29.528B 25.914B 22.476B 22.338B 19.68B 19.681B 17.685B 16.285B 13.746B
Net profit 6.524B 13.402B 5.723B 6.933B 7.071B 4.495B 3.687B 2.368B 477M 1.4B 4.423B 2.284B 2.576B 5.963B 4.728B 4.626B 5.746B 4.881B 3.606B 1.717B 3.372B 3.236B 2.753B 2.794B 1.55B 2.786B
Free cash flow 7.395B 6.351B 5.059B 7.804B 8.648B 5.724B 4.498B 4.906B 4.435B 2.082B 1.856B 2.598B 2.179B 7.519B 7.479B 7.721B 6.186B 5.707B 3.528B 3.924B 3.84B 3.014B 2.5B 2.887B — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 125.29 113.11 110.07 109.79 140.74 109.49 86.86 72.33 57.07 38.41 44.91 45.02 38.33 65.5 56.23 47.91 54.63 53.39 57.58 49.04 — — — — — —
Price performance 12m 0.11 0.03 0 -0.22 0.29 0.26 0.2 0.27 0.49 -0.14 -0 0.17 -0.41 0.16 0.17 -0.12 0.02 -0.07 0.17 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 3.25B 5.25B 5.18B 5.43B 6.41B 6.49B 6.22B 6.57B 6.93B 7.93B
↳ YoY growth -5.0% +61.6% -1.3% +4.7% +18.2% +1.1% -4.1% +5.6% +5.5% +14.5%
↳ 5y CAGR -15.8% -7.2% +5.4% +8.6% +13.4% +14.8% +3.4% +4.8% +5.0% +4.3%
Borrowings, current (USD) 1.33B 714M 207M 1.48B 220M 754M 2.25B 1.08B 1.5B 3.03B
Borrowings, non-current (USD) 20.7B 27.2B 19.4B 16.7B 18.5B 17.3B 14.5B 13.6B 12.6B 9.9B
Lease liabilities (USD) — — — 960M 1.14B 1.2B 1.17B 1.19B 1.15B 1.21B
Cash and deposits (USD) 18.6B 9.41B 3.84B 3.86B 6.84B 9.8B 9.88B 6.9B 7.62B 8.52B
Intangible assets (USD) 4.54B 21.5B 18.9B 17B 14.8B 12.7B 10.5B 8.82B 6.65B 5.53B
Right-of-use assets (USD) — — — 934M 1.1B 1.15B 1.12B 1.12B 1.08B 1.13B
Net debt (borrowings + leases - cash) (USD) 3.39B 18.5B 15.7B 15.2B 13.1B 9.45B 8.06B 8.98B 7.66B 5.61B
Cash flow detail
Operating cash flow (USD) 3.2B 5.57B 6.3B 6.14B 7.9B 10.5B 9.58B 7.26B 8.56B 9.57B
Purchases of property, plant and equipment (USD) -1.12B -1.14B -1.39B -1.64B -2.18B -1.89B -1.78B -2.2B -2.21B -2.17B
Change in receivables (cash effect) (USD) -177M -207M -190M -275M -924M -383M -68M -356M -691M -652M
Change in inventories (cash effect) (USD) -98M 249M -514M -593M -493M -456M -1.41B -232M -58M 195M
Change in payables (cash effect) (USD) -652M 615M 747M 220M 1.77B 1.29B 420M -760M 356M 954M
Dividends paid (cash effect) (USD) -1.54B -1.85B -1.97B -2.27B -2.56B -3.2B -3.31B -3.56B -3.84B -4.12B
Share buybacks (cash effect) (USD) -522M -117M -238M -718M -403M -2.3B -3.8B -1.23B -1.3B -893M
Interest paid (cash effect) (USD) -181M -917M -845M -677M -549M -544M -563M -662M -604M -545M
Income taxes paid (cash effect) (USD) -620M -570M -740M -930M -970M -1.94B -1.86B -1.48B -1.72B -1.93B
Share-based compensation (USD) 310M 406M 477M 519M 546M 640M 685M 644M 673M 664M
Operating cash flow before change in receivables (USD) 3.38B 5.78B 6.49B 6.41B 8.83B 10.9B 9.65B 7.62B 9.25B 10.2B
Free cash flow (OCF - PPE - intangibles) (USD) 2.08B 4.44B 4.91B 4.5B 5.72B 8.65B 7.8B 5.06B 6.35B 7.4B
Income detail
Research and development expense (USD) 1.42B 2.24B 2.3B 2.44B 2.42B 2.74B 2.89B 2.74B 2.84B 2.94B
↳ 5y CAGR -19.2% -12.4% +9.6% +12.7% +11.5% +14.0% +5.3% +3.6% +3.1% +4.0%
Total comprehensive income (USD) 795M 1.53B 1.18B 2.81B 4.01B 7.64B 7.26B 5.94B 13.3B 8.43B
Comprehensive income to owners (USD) 795M 1.53B 1.18B 2.81B 4.01B 7.64B 7.26B 5.94B 13.3B 8.43B
Provision for credit losses (USD) — — — — 88M 51M 6M 26M 61M 75M
Credit cost ratio (credit losses / average receivables) (%) — — — — 1.5% 0.8% 0.1% 0.4% 0.9% 1.0%
Reported Feb 17, 2017 Feb 16, 2018 Feb 22, 2019 Feb 21, 2020 Feb 19, 2021 Feb 18, 2022 Feb 17, 2023 Feb 16, 2024 Feb 21, 2025 Feb 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

As previously reported, Abbott has Agreements Regarding Change in Control (“Agreements”) with its named executive officers.

The Agreements provide that if Abbott gives notification of extension before the Expiration Date (December 31, 2026), the Agreement’s term shall continue through the second anniversary of the Expiration Date.

On November 11, 2026, Abbott notified the named executive officers, other than Robert B. Ford, Abbott’s Chairman of the Board and Chief Executive Officer, that the term of the Agreements was extended through December 31, 2028. Mr. Ford’s Agreement will expire on December 31, 2026.

–Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent

–Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42

–Expands portfolio with key new product approvals

ABBOTT PARK, Ill., Oct. 21, 2026 — Abbott today announced financial results for the third quarter ended Sept. 30, 2026.

•Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis.

•Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items.

•Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent1.

•Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted diluted EPS guidance range and tightens the range to $5.50 to $5.55.

•In August, Abbott announced U.S. Food and Drug Administration (FDA) approval for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes.

• Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies

• The new Nutrition company will be a global leader in the rapidly growing healthy nutrition market, with a portfolio of iconic, category-leading brands, including Similac, PediaSure, Pedialyte, Glucerna and Ensure

• Abbott will have accelerated sales growth and an expanded margin profile

• Abbott intends to separate its Nutrition business through a tax-free distribution to Abbott shareholders

• Separation expected to be completed by the end of 2027

ABBOTT PARK, Ill., Oct. 21, 2026 – Abbott, the global healthcare leader, today announced its intention to separate its Nutrition business into an independent publicly traded company that will be a global leader in the rapidly expanding healthy nutrition market with approximately $8.5 billion in annual sales and a portfolio of iconic brands.

“As we continue to shape Abbott for the future, this separation will benefit both companies, setting each one up for maximum success in its respective market,” said Robert B. Ford, chairman and chief executive officer, Abbott.

Prompts

Abbott Laboratories (ticker ABT), listed in United States.

ETFs Holding Abbott Laboratories

ETF Weight in ETF Shares Market value As of
DHLX 5.94% 56,996 $ 5.172M Jun 30, 2026
CTIF 4.03% 75,542 $ 7.91M Nov 18, 2026
DDDD 3.78% 2,740 $ 294.413K Nov 17, 2026
CWS 3.46% 36,630 $ 3.836M Nov 17, 2026
HRTS 3.10% 15,601 $ 1.722M Aug 31, 2026
QLTY 2.57% 1,203,746 $ 132.845M Aug 31, 2026
NPFE 2.56% 157,169 $ 16.613M Jul 31, 2026
PRVS 2.23% 6,187 $ 611.461K Sep 30, 2026
JGRW 2.19% 17,450 $ 1.926M Aug 31, 2026
FRIZ 2.09% 1,207 $ 109.523K Jun 30, 2026
MFSV 2.07% 112,708 $ 12.438M Aug 31, 2026
BEEX 1.99% 34,704 $ 3.729M Nov 17, 2026
DIVZ 1.95% 57,508 $ 5.218M Jun 30, 2026
TCAL 1.71% 52,509 $ 5.642M Nov 17, 2026
AQEC 1.48% 93,837 $ 8.515M Jun 30, 2026
FDV 1.37% 113,804 $ 12.029M Jul 31, 2026
DSTL 1.31% 307,212 $ 27.876M Jun 30, 2026
DIVD 1.19% 3,096 $ 320K Nov 18, 2026
BDVG 1.15% 1,721 $ 156.164K Jun 30, 2026
QIDX 1.14% 4,211 $ 445.103K Jul 31, 2026
FWD 1.04% 301,078 $ 33.227M Aug 31, 2026
INCE 1.03% 14,378 $ 1.305M Jun 30, 2026
CGCV 1.02% 232,851 $ 25.02M Nov 16, 2026
BALI 0.99% 141,854 $ 15.242M Nov 16, 2026
CGDV 0.96% 3,424,636 $ 367.977M Nov 16, 2026
FEAC 0.90% 2,557 $ 232.022K Jun 30, 2026
NANC 0.86% 21,617 $ 2.323M Nov 17, 2026
JDOC 0.85% 803 $ 84.082K Nov 17, 2026
CGUS 0.83% 933,572 $ 100.312M Nov 16, 2026
WBIG 0.82% 2,495 $ 226.396K Jun 30, 2026
TCAF 0.80% 802,560 $ 86.235M Nov 17, 2026
FELV 0.77% 272,380 $ 24.716M Jun 30, 2026
BMED 0.77% 1,027 $ 110.351K Nov 16, 2026
CGDG 0.76% 424,978 $ 45.664M Nov 16, 2026
NQLT 0.75% 3,329 $ 367.388K Aug 31, 2026
FHEQ 0.75% 65,844 $ 6.96M Jul 31, 2026
GDMA 0.73% 12,998 $ 1.36M Nov 18, 2026
CAPE 0.72% 18,972 $ 1.722M Jun 30, 2026
FYEE 0.71% 14,751 $ 1.559M Jul 31, 2026
DFLV 0.71% 511,793 $ 54.89M Nov 12, 2026
JDIV 0.71% 831 $ 87.014K Nov 17, 2026
DFUV 0.69% 1,009,458 $ 108.264M Nov 12, 2026
OEI 0.65% 2,864 $ 302.725K Jul 31, 2026
SPIN 0.61% 2,523 $ 271.096K Nov 16, 2026
NBCR 0.59% 45,897 $ 5.065M Aug 31, 2026
VFMV 0.59% 24,108 $ 2.661M Aug 31, 2026
MFSG 0.54% 18,499 $ 2.042M Aug 31, 2026
BDYN 0.53% 149,988 $ 16.116M Nov 16, 2026
JAVA 0.53% 374,257 $ 39.188M Nov 17, 2026
SFGV 0.53% 58,356 $ 6.11M Nov 18, 2026
PAPI 0.52% 22,761 $ 2.065M Jun 30, 2026
FELC 0.51% 446,227 $ 40.491M Jun 30, 2026
BALQ 0.49% 1,939 $ 208.346K Nov 16, 2026
VFVA 0.48% 41,353 $ 4.564M Aug 31, 2026
MSLC 0.44% 163,528 $ 18.047M Aug 31, 2026
BTAL 0.44% 13,662 $ 1.24M Jun 30, 2026
MPLY 0.43% 652 $ 68.916K Jul 31, 2026
XMAG 0.42% 8,534 $ 915.272K Nov 13, 2026
ACVF 0.40% 5,717 $ 604.287K Jul 31, 2026
LDRX 0.38% 8,837 $ 975.251K Aug 31, 2026
LGDX 0.38% 4,858 $ 521.992K Nov 17, 2026
RDVI 0.37% 131,064 $ 14.324M Nov 11, 2026
PSTR 0.35% 2,151 $ 237.384K Aug 31, 2026
ACIO 0.35% 78,027 $ 8.247M Jul 31, 2026
ADME 0.35% 9,579 $ 1.013M Jul 31, 2026
CLSE short -0.34% -28,035 $ -3.094M Aug 31, 2026
MODL 0.34% 37,894 $ 3.439M Jun 30, 2026
TACU 0.32% 547 $ 58.775K Nov 17, 2026
LCTU 0.32% 33,286 $ 3.577M Nov 16, 2026
GEW 0.31% 4,093 $ 451.703K Aug 31, 2026
ENHU 0.30% 263 $ 28.259K Nov 16, 2026
HUSV 0.30% 1,617 $ 173.747K Nov 16, 2026
STOX 0.29% 5,889 $ 649.91K Aug 31, 2026
LVDS 0.29% 3,310 $ 346.59K Nov 17, 2026
VOXP 0.29% 159 $ 16.806K Jul 31, 2026
SFTY 0.28% 20,250 $ 2.235M Aug 31, 2026
GSPY 0.28% 17,697 $ 1.902M Nov 17, 2026
DFUS 0.27% 535,551 $ 57.438M Nov 12, 2026
INRO 0.26% 14,333 $ 1.54M Nov 16, 2026
APUE 0.26% 58,168 $ 6.419M Aug 31, 2026
GDE 0.24% 10,618 $ 1.172M Aug 31, 2026
CDX 0.24% 5,720.4582 $ 598.989K Nov 17, 2026
DFVX 0.24% 12,616 $ 1.353M Nov 12, 2026
HCMT 0.23% 12,118 $ 1.281M Jul 31, 2026
JEPI 0.22% 976,457 $ 102.245M Nov 17, 2026
NTSX 0.21% 31,733 $ 2.879M Jun 30, 2026
WSGE 0.21% 1,207 $ 126.385K Nov 18, 2026
NTSD 0.20% 771 $ 69.961K Jun 30, 2026
DFAU 0.19% 229,614 $ 24.626M Nov 12, 2026
JGRO 0.19% 164,358 $ 17.21M Nov 17, 2026
VSLU 0.18% 11,093 $ 1.007M Jun 30, 2026
DCOR 0.18% 769,486 $ 82.527M Nov 12, 2026
AVSU 0.18% 7,856 $ 844.127K Nov 16, 2026
HEQQ 0.18% 492 $ 51.517K Nov 17, 2026
AAUS 0.18% 8,532 $ 890K Nov 18, 2026
AVUS 0.17% 225,043 $ 24.181M Nov 16, 2026
DFAC 0.17% 1,352,486 $ 145.054M Nov 12, 2026
AVLC 0.16% 23,788 $ 2.556M Nov 16, 2026
JUSA 0.16% 13,083 $ 1.37M Nov 17, 2026
IALT short -0.14% -105,250 $ -11.309M Nov 16, 2026